SCHEMBL21152873

SCHEMBL21152873

CC(C)N[C@H](CCC(=O)O)C(=O)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 7/20 0.44
NAALAD2 Q9Y3Q0 2/20 0.44
RIMKLA Q8IXN7 1/20 0.44
GABRP O00591 2/20 0.43
GABRD O14764 2/20 0.43
GABRA1 P14867 2/20 0.43
GABRB1 P18505 2/20 0.43
GABRG2 P18507 2/20 0.43
GABRB3 P28472 2/20 0.43
GABRA5 P31644 2/20 0.43
GABRA3 P34903 2/20 0.43
GABRA2 P47869 2/20 0.43
GABRB2 P47870 2/20 0.43
GABRA4 P48169 2/20 0.43
GABRE P78334 2/20 0.43
GABRA6 Q16445 2/20 0.43
GABRG1 Q8N1C3 2/20 0.43
GABRG3 Q99928 2/20 0.43
GABRQ Q9UN88 2/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22479743 1.00 FOLH1 (0.44) FOLH1NAALAD2RIMKLAGABRPGABRD
SCHEMBL7602617 1.00 FOLH1 (0.44) FOLH1NAALAD2RIMKLAGABRPGABRD
SCHEMBL24533098 0.89 GABRP (0.36) FOLH1GABRPGABRDGABRA1GABRB1
SCHEMBL24533099 0.87 FFAR4 (0.41) ENPEPKDM4AKDM4CKDM2A
SCHEMBL14765596 0.86 FOLH1 (0.45) FOLH1NAALAD2RIMKLAGABRPGABRD
SCHEMBL25453237 0.86 FOLH1 (0.45) FOLH1NAALAD2RIMKLAGABRPGABRD
SCHEMBL21152805 0.86 FOLH1 (0.45) FOLH1NAALAD2RIMKLAGABRPGABRD
SCHEMBL4623229 0.84 GABRP (0.48) FOLH1NAALAD2RIMKLAGABRPGABRD
SCHEMBL13707913 0.84 GABRP (0.48) FOLH1NAALAD2RIMKLAGABRPGABRD
SCHEMBL22844805 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240209382-A1 NANOPARTICLES AND BIOTEMPLATES WITH TUNABLE LENGTH AND METHODS OF MANUFACTURING THE SAME UNIVERSITY OF DELAWARE 2024-06-27 US disclosed
US-20240209382-A1 NANOPARTICLES AND BIOTEMPLATES WITH TUNABLE LENGTH AND METHODS OF MANUFACTURING THE SAME UNIVERSITY OF DELAWARE 2024-06-27 US disclosed
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same Sumitomo Pharma Co., Ltd. (JP) 2024-06-25 US disclosed
US-20230151074-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-05-18 US disclosed
US-20200247845-A1 Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-08-06 US disclosed
US-20190209702-A1 STEROIDS AND ANTIBODY-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190209702-A1 STEROIDS AND ANTIBODY-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 FOLH1 895/4885NAALAD2 1893/4885RIMKLA 3690/4885
US-20240209382-A1 NANOPARTICLES AND BIOTEMPLATES WITH TUNABLE LENGTH AND METHODS OF MANUFACTURING THE SAME RNGTT, HBS1L, BROX FOLH1 1684/4885NAALAD2 1768/4885RIMKLA 1153/4885
US-20200247845-A1 Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same FCGRT, QARS1, INHA FOLH1 4072/4885NAALAD2 984/4885RIMKLA 1754/4885
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same FCGRT, QARS1, INHA FOLH1 4072/4885NAALAD2 984/4885RIMKLA 1754/4885
US-20230151074-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR FOLH1 2850/4885NAALAD2 3073/4885RIMKLA 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.